<DOC>
	<DOCNO>NCT00667017</DOCNO>
	<brief_summary>RATIONALE : Immunotoxins , RFT5-dgA immunotoxin ( also call anti-CD25 immunotoxin IMTOX25 ) , find certain cancer cell kill without harm normal cell . PURPOSE : This phase II trial study side effect anti-CD25 immunotoxin IMTOX25 well work treat patient relapsed refractory cutaneous T-cell non-Hodgkin lymphoma .</brief_summary>
	<brief_title>RFT5-dgA Immunotoxin Treating Patients With Relapsed Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient relapse refractory cutaneous T-cell non-Hodgkin lymphoma ( CTCL ) follow treatment RFT5-dgA immunotoxin ( anti-CD25 immunotoxin IMTOX25 ) . Secondary - Determine whether response correlate level CD25+ expression CTCL tumor cell . - Determine whether change pre-treatment post-treatment level CD4+CD25+ Treg cell correlate response . OUTLINE : Patients receive anti-CD25 immunotoxin IMTOX25 IV 4 hour day 1 , 3 , 5 . Treatment repeat every 6 week 6 course absence disease progression unacceptable toxicity . Tissue blood sample collect baseline , study CD25+ expression fluorescent-activated cell sorter analysis , immunohistochemistry . After completion study therapy , patient follow every 3 month 2 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cutaneous Tcell nonHodgkin lymphoma ( CTCL ) Relapsed refractory disease , meet 1 follow criterion : Progression disease follow 2 prior chemotherapy Failure respond second prior chemotherapy Measurable disease PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month Serum creatinine &lt; 1.5 time upper limit normal ( ULN ) Serum AST/ALT &lt; 2.5 time ULN Total bilirubin ≤ 2.0 mg/dL ( &lt; 3.0 mg/dL patient Gilbert syndrome ) WBC count ≥ 3,000/mm³ Platelet count ≥ 100,000/mm³ Serum albumin &gt; 2.5 g/dL LVEF ≥ 45 % 2D ECHO MUGA scan Human antimurine antibody &lt; 1 μg/mL Patients history electrocardiogram abnormality , symptom cardiac ischemia , arrhythmias must normal cardiac stress test ( i.e. , stress thallium , stress MUGA , dobutamine echocardiogram , stress test ) Must willing undergo venipuncture central line placement Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No HBV surface antigen , HCV , HIV antibody positivity No autoimmune disease immunodeficiency ( i.e. , HIV ) No history uncontrolled concurrent illness include , limited , follow : Ongoing active infection Ongoing active cardiac disease ( i.e. , congestive heart failure , unstable angina pectoris , cardiac arrhythmia ) Psychiatric illness and/or social situation would preclude study compliance No malignancy except treat basal cell squamous cell carcinoma skin , treat carcinoma situ cervix PRIOR CONCURRENT THERAPY : See Disease Characteristics More 3 week since prior systemic therapy CTCL More 6 month since prior chronic steroid therapy chronic anticoagulation therapy No prior therapy antiCD25 immunotoxin IMTOX25 and/or Ontak No concurrent cancer chemotherapy , experimental therapy , investigational agent , immunomodulating agent ( include steroid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>